Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Mallinckrodt
Argus Health
Farmers Insurance
Moodys
Accenture

Generated: April 24, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OXYCODONE

« Back to Dashboard

Clinical Trials for oxycodone

Trial ID Title Status Sponsor Phase Summary
NCT00000273 A Laboratory Model for Heroin Abuse Medications - 8 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
NCT00000273 A Laboratory Model for Heroin Abuse Medications - 8 Completed New York State Psychiatric Institute Phase 2 The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
NCT00027014 Herb-Opioid Interactions Completed National Center for Complementary and Integrative Health (NCCIH) Phase 4 This is a series of studies in healthy volunteers to assess the potential for adverse interactions between St. John's wort (SJW) extract and two narcotic (opioid) pain medications: oxycodone and fentanyl. In the case of oxycodone, we are interested in whether SJW treatment promotes the metabolism of oxycodone, such that it lowers the effectiveness of standard doses of oxycodone in treating pain problems. For the fentanyl study, we will investigate whether SJW treatment will interfere with the delivery of fentanyl to the brain and diminish it's effectiveness to relieve pain. There is evidence to suggest that SJW treatment may increase the activity of a transporter protein, named P-glycoprotein (Pgp), in the blood-brain barrier (BBB) that protects the brain from exposure to drugs and other dietary and environmental toxins.
NCT00092313 A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
NCT00092326 A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
NCT00158184 Prescription Opioid Effects in Abusers Versus Non-Abusers Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to examine the abuse liability of oxycodone and codeine in individuals with, and without, a history of prescription opioid abuse. The subjective and reinforcing effects of each drug will also be examined in the presence, and absence, of experimentally induced pain.
NCT00158184 Prescription Opioid Effects in Abusers Versus Non-Abusers Completed New York State Psychiatric Institute Phase 2 The purpose of this study is to examine the abuse liability of oxycodone and codeine in individuals with, and without, a history of prescription opioid abuse. The subjective and reinforcing effects of each drug will also be examined in the presence, and absence, of experimentally induced pain.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for oxycodone

Condition Name

Condition Name for oxycodone
Intervention Trials
Pain 80
Pain, Postoperative 32
Postoperative Pain 31
Healthy 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for oxycodone
Intervention Trials
Pain, Postoperative 90
Back Pain 29
Low Back Pain 26
Osteoarthritis 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for oxycodone

Trials by Country

Trials by Country for oxycodone
Location Trials
United States 884
China 28
Canada 24
Finland 19
Italy 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for oxycodone
Location Trials
New York 60
California 50
Texas 49
Pennsylvania 44
Florida 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for oxycodone

Clinical Trial Phase

Clinical Trial Phase for oxycodone
Clinical Trial Phase Trials
Phase 4 137
Phase 3 99
Phase 2/Phase 3 4
[disabled in preview] 105
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for oxycodone
Clinical Trial Phase Trials
Completed 210
Recruiting 76
Not yet recruiting 64
[disabled in preview] 63
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for oxycodone

Sponsor Name

Sponsor Name for oxycodone
Sponsor Trials
Purdue Pharma LP 23
GrĂ¼nenthal GmbH 19
Pfizer 17
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for oxycodone
Sponsor Trials
Other 313
Industry 211
NIH 21
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Cantor Fitzgerald
Express Scripts
Fuji
Accenture
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.